Clexane

Prophylaxis of VTE disease associated w/ orthopedic or general surgery & in medical patients bedridden due to acute illnesses. Established DVT. Prevention of thrombus formation in extracorporeal circulation during haemodialysis. Unstable angina & non-Q-wave MI (concurrently w/ aspirin). Acute ST-segment elevation MI (STEMI) (in combination w/ a thrombolytic agent) in patients to be managed medically or w/ subsequent percutaneous coronary intervention (PCI).

Prophylaxis of VTE disease Patient w/ moderate thromboembolism risk (eg, abdominal surgery) 2,000 anti-Xa IU (0.2 mL) SC once daily. General surgery 1st inj to be given 2 hr before the surgical procedure. Patient w/ high risk of thromboembolic (eg, orthopedic surgery) 4,000 anti-Xa IU (0.4 mL) SC once daily initiated 12 hr pre-op. Duration of treatment is usually 7-10 days. Medical patient 4,000 anti-Xa IU (0.4 mL) SC once daily for min of 6 days & continued until the return to full ambulation for max of 14 days. Established DVT 100 anti-Xa IU/kg SC every 12 hr for 10 days. Prevention of extracorporeal thrombus formation during haemodialysis 100 anti-Xa IU/kg (1 mg/kg) introduced into the arterial line at the beginning of dialysis session, sufficient for a 4-hr session. A further dose of 50-100 anti-Xa IU/kg (0.5-1 mg/kg) may be given if fibrin rings are found eg, after a longer than normal session. Patient at higher risk of haemorrhage Reduce dose to 50 anti-Xa IU/kg (0.5 mg/kg) for double vascular access or 75 anti-Xa IU/kg (0.75 mg/kg) for a single vascular access. Unstable angina & non-Q-wave MI 100 anti-Xa IU/kg (1 mg/kg) SC every 12 hr (w/ aspirin 100-325 mg once daily) for 2-8 days until clinical stabilisation of patient. Acute STEMI in combination w/ a thrombolytic agent in patient eligible or not for subsequent PCI Initial IV bolus inj of 3,000 anti-Xa IU (0.3 mL) followed by 100 anti-Xa IU/kg SC w/in 15 min then every 12 hr. Max dose: 10,000 anti-Xa IU (1 mL) for the 1st 2 SC doses only, followed by 100 anti-Xa IU/kg SC for the remaining doses. 1st dose: Administer anytime between 15-30 min after the start of thrombolytic treatment. Recommended duration: 8 days or until hospital discharge. Elderly ≥75 yr 75 anti-Xa IU/kg SC every 12 hr. Max dose: 7,500 anti-Xa IU for each of the 1st 2 SC doses only, followed by 75 anti-Xa IU/kg dosing the remaining doses. Patient managed w/ PCI Last enoxaparin SC inj performed <8 hr before balloon inflation, no additional administration is necessary. Last SC inj performed >8 hr before balloon inflation, administer 30 anti-Xa IU/kg IV bolus. Severe renal impairment (CrCl <30 mL/min) Prophylactic dose range: 2,000 anti-Xa IU SC once daily. Therapeutic dose range: 100 anti-Xa IU/kg SC once daily. Acute STEMI in elderly patient ≥75 yr 100 anti-Xa IU/kg SC once daily w/o initial bolus. Max: 10,000 anti-Xa IU for 1st SC dose only. Acute STEMI in patient <75 yr 3,000 anti-Xa IU single IV bolus + 100 anti-Xa IU/kg SC dose followed by 100 anti-Xa IU/kg SC once daily. Max: 10,000 anti-Xa IU for 1st SC dose only.

Hypersensitivity to enoxaparin Na, heparin or other LMWH. Acute bacteria endocarditis; active major bleeding disorders & conditions w/ high risk of uncontrolled haemorrhage including haemorrhagic stroke (unless due to systemic emboli); thrombocytopenia in patients w/ a positive in-vitro aggregation test in the presence of enoxaparin; acute gastric or duodenal ulceration.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB05 - enoxaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.

POM